Clinical trial · Observational
Post-Marketing Surveillance of Lenvima in Korean Patients
NCT02764554CI-TRIAL-00054338completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Carcinoma (DTC) | Differentiated Thyroid Gland Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Lenvatinib 4 milligram (mg) and 10 mg capsule
- description
- Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
Primary outcomes (1)
- measure
- Number of Participants with Adverse Events, Serious Adverse Events, and Adverse Drug Reactions
- timeFrame
- Up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria: Participants who meet the following criteria will be eligible for inclusion in the study: 1. Participants with approved indication for lenvatinib in Korea 2. Participants who have written consent for use of personal and medical information for the study purpose Exclusion Criteria: Investigators will refer to approved indications and contraindications regarding exclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.